Crinetics Pharmaceuticals, Inc. (CRNX)
Quantitative Summary
DeterministicBelow-average fundamentals indicated by Piotroski score of 2/9. Beneish M-Score of 5.75 exceeds the -2.22 academic threshold — earnings quality may warrant further review.
Generated deterministically from quant metrics and financial statements. Not a recommendation.
Price Chart with Moving Averages
Quant Health Deep Dive
Profitability & Value Creation
Balance Sheet Health
Earnings Surprise History
EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Fundamentals
Passive Flow Attribution
ETF Draft EffectWhen investors buy or sell ETFs like XPH or VTWO, the fund manager is mechanically forced to buy or sell CRNX shares regardless of Crinetics Pharmaceuticals, Inc.'s individual fundamentals. We estimate $75M of passive capital is structurally linked to CRNX through 4 tracked ETFs. Passive flows have a limited but growing influence on CRNX's daily trading dynamics.
Passive exposure = Σ (ETF AUM × stock weight in ETF) across 4 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.
ETF Contagion Visualizer
Simulate a price drop in Crinetics Pharmaceuticals, Inc. to visualize passive redemption contagion across ETFs and collateral stocks.
If Crinetics Pharmaceuticals, Inc. (CRNX) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies Eli Lilly & Co. (LLY) as the most exposed collateral stock, sharing 1 ETFs with CRNX. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.
Contagion model based on shared ETF exposure and constituent weights across 4 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.
CRNX Ownership Dynamics
ETFs with Highest CRNX Exposure
Float lock-up computed from 4 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).
CRNX Institutional Volume Profile
252-day volume distribution by price level. The Point of Control (POC) marks — the price where the most institutional volume transacted — an implicit support/resistance floor.
The highest-volume price zone for Crinetics Pharmaceuticals, Inc. over the past year sits near $82.19 (25% of 252-day volume). The current price of $83.62 trades 1.7% above this institutional floor — a sign of upside momentum, though a pullback to the POC zone is a common reversion target. The highly concentrated volume profile (25% at POC) indicates strong consensus on fair value — institutional participants have repeatedly transacted near this price.
Volume Profile computed from 252 trading days of OHLCV data. Volume allocated to price bins proportionally based on daily high-low range. Not investment advice.
Fails-to-Deliver (FTD) History
SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.
| Date | Failed Shares | Close Price | Notional Value |
|---|---|---|---|
| 2026-06-10 | 21,030 | $34.97 | $735,419.1 |
| 2026-06-02 | 1,500 | $34.52 | $51,780 |
| 2026-05-28 | 251 | $36.79 | $9,234.29 |
| 2026-05-21 | 5 | $36.27 | $181.35 |
| 2026-04-20 | 6,703 | $41.00 | $274,823 |
| 2026-04-13 | 1,792 | $39.44 | $70,676.48 |
| 2026-04-08 | 150 | $38.41 | $5,761.5 |
| 2026-04-06 | 24 | $37.23 | $893.52 |
| 2026-04-02 | 49,064 | $36.57 | $1.8M |
| 2026-03-24 | 255 | $34.71 | $8,851.05 |
| 2026-03-23 | 1 | $35.57 | $35.57 |
| 2026-03-20 | 399 | $35.82 | $14,292.18 |
| 2026-03-18 | 65 | $37.89 | $2,462.85 |
| 2026-03-17 | 1,857 | $37.28 | $69,228.96 |
| 2026-03-11 | 41 | $37.35 | $1,531.35 |
| 2026-03-10 | 4,529 | $38.22 | $173,098.38 |
| 2026-02-13 | 2,026 | $44.08 | $89,306.08 |
| 2026-02-09 | 5,774 | $45.28 | $261,446.72 |
| 2026-01-21 | 18 | $55.69 | $1,002.42 |
| 2026-01-16 | 10,672 | $56.43 | $602,220.96 |
| 2026-01-13 | 6,978 | $55.35 | $386,232.3 |
| 2026-01-05 | 1,850 | $46.73 | $86,450.5 |
| 2025-12-31 | 6,091 | $47.39 | $288,652.49 |
| 2025-12-30 | 2,193 | $47.52 | $104,211.36 |
| 2025-12-22 | 65,595 | $48.01 | $3.1M |
| 2025-12-19 | 900 | $45.14 | $40,626 |
| 2025-12-08 | 2,338 | $46.67 | $109,114.46 |
| 2025-12-05 | 1,257 | $47.42 | $59,606.94 |
| 2025-12-02 | 2,993 | $45.25 | $135,433.25 |
| 2025-11-28 | 209,231 | $46.03 | $9.6M |
Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.
Compare CRNX to Peers
Quant metrics computed deterministically from financial statements and price data. Updated: 2026-07-09.
SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.